Sort   by:  
 Page size 
UnknownMaraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Not available
S-EPMC5853584 | biostudies-literature
UnknownWhy START? Reflections that led to the conduct of this large long-term strategic HIV trial.
Not available
S-EPMC4347998 | biostudies-literature
Sort   by:  
 Page size